Travivo (Gepirone ER)

[Lusitanic]

Anyone knows or tried this AD med?


Travivo (Gepirone ER)
Mechanism: 5-HT1A selective partial agonist
Status: Pending FDA approval
Developer: Fabre-Kramer Pharmaceuticals
Travivo (Gepirone ER) is an antidepressant medication that was initially rejected multiple times by the FDA due to concerns of efficacy. It was first rejected in 2004, then again in 2007. That said, the FDA reviewed data for Gepirone in 2015 and reversed their initial rejection of the drug – giving it a favorable review. As of January 2018, Gepirone is awaiting pre-approval from the FDA and is likely to hit markets within the next year under the brand name “Travivo.”

I’ve already written about using Travivo for depression and anxiety disorders. The drug is in the same azapirone classification as Buspar (buspirone) but functions slightly differently in that exerts a greater effect upon 5-HT1A receptors as a partial agonist – and has limited interaction with the D2 receptor. Essentially, Travivo may be like a slightly altered version of Buspar for anxiety with a much stronger antidepressant effect.

Considering its mechanism of action, it’s reasonable to speculate that Travivo will be useful for anxious-depression (i.e. anxiodepressive disorders). What’s more, research suggests that Travivo exhibits pro-sexual effects whereby it may reverse sexual dysfunction in men and women; these pro-sexual effects are independent of its antidepressant and anxiolytic action. Though not a new medication, I suspect that Travivo will be one of the safer psychiatric drugs if and when it hits the market.

http://www.fabrekramer.com/?page_id=414

[Lusitanic]

It will reach US market in 2020.

[tenacity]

Thank you for this post! It seems like an interesting drug.